Please disable Ad Blocker before you can visit the website !!!

Johnson & Johnson LONG

by SignalFactory   ·  July 15, 2020 | 10:39:40 UTC  

Johnson & Johnson LONG

by SignalFactory   ·  July 15, 2020 | 10:39:40 UTC  

We expect Johnson & Johnson JNJ to beat expectations when it reports second-quarter 2020 results on Jul 16, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 13.30%.

The healthcare bellwether’s performance has been impressive, with the company exceeding earnings expectations in each of the trailing four quarters. The company has a four-quarter positive earnings surprise of 6.75%, on average.

Factors to Consider:

Sales in J&J’s Pharmaceutical segments are expected to have grown above the market in the second quarter despite currency headwinds and the impact of biosimilar and generic competition on Remicade and Procrit sales. The increase is expected to have been led by the company’s oncology drugs Imbruvica and Darzalex as well as a psoriasis treatment, Stelara.

Meanwhile, incremental COVID-19 demand benefited sales of Imbruvica, Xarelto, Stelara, the PAH portfolio, and HIV products in the first quarter. However, a small level of disruption associated with delayed diagnosis and new patient starts is expected to have hurt sales of some drugs in the second quarter.

Sales in J&J’s Medical Devices unit were hurt by a widespread decline in elective surgical procedures and redeployment of hospital resources to address patients affected by the pandemic in the first quarter. The negative impact seen in the Medical Devices unit is expected to have been more significant in the second quarter. However, in April, J&J had said that elective procedures will recover in the third quarter and improve in the fourth quarter. An update is expected on the conference call.

In the Consumer Healthcare segment, demand for products like Tylenol analgesics and Listerine mouthwash increased in the first quarter as consumers under lockdown stocked up basic medicines and consumer products. However, J&J expects some of the coronavirus related benefit seen in the Consumer Health segment in the first quarter, mainly its over-the-counter medicines, to reverse over the second and remaining quarters of 2020. We expect Consumer Healthcare segment sales in the second quarter to have been sequentially lower than the first quarter. J&J expects sales in certain categories like skincare to be hurt because of reduced store traffic and social distancing in the second quarter.

The Zacks Consensus Estimate for Imbruvica, Darzalex, and Stelara is pegged at $1.09 billion, $911 million, and $1.79 billion, respectively. Please note that J&J markets Imbruvica in partnership with AbbVie (NYSE: ABBV).

Importantly, investors will also focus on whether J&J provides an updated business outlook for 2020 to update on the impact of coronavirus.

In April, J&J had said that its major regulatory filings and approvals planned for 2020 are on track and no delay is expected for the pandemic. An update is expected on the second-quarter conference call.

J&J is likely to face questions on the call related to a Missouri appeals court decision to overturn a St. Louis jury verdict given in 2018 to pay $4.69 billion in damages to 22 women who claimed that J&J’s talc-based products caused them to develop ovarian cancer. The court, however, reduced the verdict to $2.1 billion arguing that 17 of the 22 plaintiffs were not from Missouri and should not have been included in the verdict. In the first quarter, J&J also announced that it is permanently discontinuing the sale of its talc-based Johnson’s Baby Powder in the United States and Canada.

Key Recent Development:

In June, J&J said that it is accelerating the timeline for initiation of phase I/II human clinical study on its vaccine candidate for COVID-19 to the second half of July rather than September as announced earlier. The phase I/II study will be conducted in 1045 healthy adults aged 18 to 55 years, plus adults aged 65 years and older and will be initiated in the United States and Belgium. J&J said that it is holding talks with the National Institutes of Allergy and Infectious Diseases to begin pivotal phase III studies on the candidate sooner than planned if data from the phase I/II study is positive.

J&J’s goal is to supply more than 1 billion doses of the vaccine globally if it proves to be safe and effective.

J&J looks confident of having the first batch of COVID-19 vaccine available for emergency use authorization, on a not-for-profit basis, by early 2021. J&J is committed to investing more than $1 billion in partnership with Biomedical Advanced Research and Development Authority (BARDA) to co-fund vaccine research, development, and clinical testing.

Johnson & Johnson LONG (Buy)

ENTER AT: 148.99

T.P_1: 154.79

T.P_2: 164.10


S.L: 138.07

Johnson & Johnson
Johnson & Johnson
All information on this website is of a general nature. The information is not adapted to conditions that are specific to your person or entity. The information provided can not be considered as personal, professional or legal advice or investment advice to the user. This website and all information is intended for educational purposes only and does not give financial advice. Signal Factory is not a service to provide legal and financial advice; any information provided here is only the personal opinion of the author (not advice or financial advice in any sense, and in the sense of any act, ordinance or law of any country) and must not be used for financial activities. Signal Factory does not offer, operate or provide financial, brokerage, commercial or investment services and is not a financial advisor. Rather, Signal Factory is an educational site and a platform for exchanging Forex information. Whenever information is disclosed, whether express or implied, about profit or revenue, it is not a guarantee. No method or trading system ensures that it will generate a profit, so always remember that trade can lead to a loss. Trading responsibility, whether resulting in profits or losses, is yours and you must agree not to hold Signal Factory or other information providers that are responsible in any way whatsoever. The use of the system means that the user accepts Disclaimer and Terms of Use. Signal Factory is not represented as a registered investment consultant or brokerage dealer nor offers to buy or sell any of the financial instruments mentioned in the service offered. While Signal Factory believes that the content provided is accurate, there are no explicit or implied warranties of accuracy. The information provided is believed to be reliable; Signal Factory does not guarantee the accuracy or completeness of the information provided. Third parties refer to Signal Factory to provide technology and information if a third party fails, and then there is a risk that the information may be delayed or not delivered at all. All information and comments contained on this website, including but not limited to, opinions, analyzes, news, prices, research, and general, do not constitute investment advice or an invitation to buy or sell any type of instrument. Signal Factory assumes no responsibility for any loss or damage that may result, directly or indirectly, from the use or dependence on such information. All information contained on this web site is a personal opinion or belief of the author. None of these data is a recommendation or financial advice in any sense, also within the meaning of any commercial act or law. Writers, publishers and affiliates of Signal Factory are not responsible for your trading in any way. The information and opinions contained in the site are provided for information only and for educational reasons, should never be considered as direct or indirect advice to open a trading account and / or invest money in Forex trading with any Forex company . Signal Factory assumes no responsibility for any decisions taken by the user to create a merchant account with any of the brokers listed on this website. Anyone who decides to set up a merchant account or use the services, free of charge or paid, to any of the Forex companies mentioned on this website, bears full responsibility for their actions. Any institution that offers a service and is listed on this website, including forex brokers, financial companies and other institutions, is present only for informational purposes. All ratings, ratings, banners, reviews, or other information found for any of the above-mentioned institutions are provided in a strictly objective manner and according to the best possible reflection of the materials on the official website of the company. Forex trading is potentially high risk and may not be suitable for all investors. The high level of leverage can work both for and against merchants. Before each Forex investment, you should carefully consider your goals, past experience and risk level. The opinions and data contained on this site should not be considered as suggestions or advice for the sale or purchase of currency or other instruments. Past results do not show or guarantee future results. Neither Signal Factory nor its affiliates ensure the accuracy of the content provided on this Site. You explicitly agree that viewing, visiting or using this website is at your own risk.

Signal Factory is now on Telegram

make sure to join our Telegram channel now and you will not miss any update